COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology
NCT ID: NCT04335773
Last Updated: 2022-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
350 participants
OBSERVATIONAL
2020-04-03
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Characteristics and Outcomes of Pediatric COVID-19
NCT04330261
Effect of COVID-19 Pandemic on Vaccination Compliance
NCT04618796
Severe COVID-19 Infection in Children Presenting to EDs in Israel and England
NCT06434701
Point-of-care Testing of Respiratory Pathogens at Pediatric Emergency Room
NCT03932942
Evaluation of the Prevalence of Anti-infective Drug Compliance in Pediatric Patients Hospitalized at Nimes University Hospital After Return Home
NCT04009785
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Children (0-18 years of age) admitted to hospital with suspected COVID-19 are eligible (Fig. 1). Those with confirmed COVID-19 serve as cases, whereas those with non-COVID-19 serve as controls; both groups will be followed prospectively for 6 months. Three objectives/Work Packages (WPs) are defined:
* In WP1, the investigators will investigate risk factors for severe outcome of the acute infection; potential risk factors include sex, age, comorbidities, initial clinical findings, infectious load, and genetic markers.
* In WP2, the investigators will investigate the immunological response to acute infection, focusing on initial innate host response and its associations to inflammatory enhancement, genetic factors and clinical course.
* In WP3, the investigators will investigate the prevalence and risk factors of long-lasting complication, in particular the development of post-infectious chronic fatigue
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sars-CoV-2 positive
Children positive for SARS-CoV-2
No interventions assigned to this group
SARS-CoV-2 negative
Children negative SARS-CoV-2
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Olavs Hospital
OTHER
Helse Stavanger HF
OTHER_GOV
Haukeland University Hospital
OTHER
University Hospital of North Norway
OTHER
Alesund Hospital
OTHER
Norwegian Institute of Public Health
OTHER_GOV
The University of New South Wales
OTHER
University of Bristol
OTHER
Sykehuset Ostfold
OTHER
Nordlandssykehuset HF
OTHER
Vestre Viken Hospital Trust
OTHER
Helse Fonna
OTHER
Helse Nord-Trøndelag HF
OTHER
Oslo University Hospital
OTHER
Sykehuset Innlandet HF
OTHER
University Hospital, Akershus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christopher Inchley
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Akershus universistetssykehus
Lørenskog, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20/03794
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.